Medtech M&A remains hot: Here’s how

M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig.

Having a strategic patent portfolio tied to business goals can be a key to attracting buyers and venture capital financing for early-stage companies with innovative technology and a solid management team, according to Dykeman. Patents are often the only way for investors to place value on an early-stage company’s technology and judge the potential success before sales, which often only begin after FDA regulatory approval. Strategic patents can also lead to joint ventures, collaborations and licenses with strategic partnerships.

At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.